Thierry Façon

Active 1991–2025

Also published as
Thierry Facon
227
Papers
54,077
Citations
112
h-index
217
i10-index

Citations

Citations per year for Thierry Façon1948: 4 citations1988: 5 citations1990: 1 citations1992: 2 citations1993: 8 citations1994: 13 citations1995: 13 citations1996: 20 citations1997: 17 citations1998: 35 citations1999: 41 citations2000: 68 citations2001: 80 citations2002: 105 citations2003: 170 citations2004: 159 citations2005: 147 citations2006: 223 citations2007: 280 citations2008: 276 citations2009: 369 citations2010: 346 citations2011: 381 citations2012: 289 citations2013: 362 citations2014: 314 citations2015: 323 citations2016: 343 citations2017: 424 citations2018: 354 citations2019: 1,462 citations2020: 1,902 citations2021: 2,010 citations2022: 1,578 citations2023: 1,097 citations2024: 1,641 citations2025: 654 citations2026: 14 citations1949–1987: no citations, so these years are not shown1989: no citations, so this year is not shown1991: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,619 citing papers, 25.6% of this breakdownItaly: 918 citing papers, 6.5% of this breakdownUnited Kingdom: 886 citing papers, 6.3% of this breakdownGermany: 882 citing papers, 6.2% of this breakdownFrance: 838 citing papers, 5.9% of this breakdownChina: 827 citing papers, 5.9% of this breakdownSpain: 704 citing papers, 5% of this breakdownCanada: 487 citing papers, 3.5% of this breakdownNetherlands: 445 citing papers, 3.2% of this breakdownAustralia: 390 citing papers, 2.8% of this breakdownGreece: 379 citing papers, 2.7% of this breakdownJapan: 315 citing papers, 2.2% of this breakdown
0%25.6%Other 24.2%

Fields

  • Medicine77.1%
  • Biochemistry, Genetics and Molecular Biology18.8%
  • Immunology and Microbiology2%
  • Computer Science0.5%
  • Chemistry0.3%
  • Mathematics0.2%
  • Other1.1%

Topics

  • Multiple Myeloma Research and Treatments19.3%
  • Protein Degradation and Inhibitors8.9%
  • Peptidase Inhibition and Analysis4.4%
  • Ubiquitin and proteasome pathways3.3%
  • Cancer Treatment and Pharmacology3%
  • CAR-T cell therapy research2.7%
  • Other58.4%

Coauthors

All papers

Open in search
  1. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philippe Moreau - Journal of Clinical Oncology 2015 cited by 2,178

  2. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.

    Authors: , , , , , , , , , , , , , , , , - Annals of Oncology 2021 cited by 820

  3. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Soraya Wuillème, Sonja Zweegman, Brigitte Kolb, Cyrille Touzeau, Murielle Roussel, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Jean Paul Fermand, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Sen Hong Zhuang, Christopher Chiu, Lixia Pei, Carla de Boer, Elena Smith, William Deraedt, Tobias Kampfenkel, Jordan M. Schecter, Jessica Vermeulen, Hervé Avet‐Loiseau, Pieter Sonneveld - The Lancet 2019 cited by 953

  4. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eric Lewis, Roxanne C. Jewell, Elisha J. Dettman, Rakesh Popat, Simona Degli Esposti, Joanna Opalinska, Paul G. Richardson, Adam D. Cohen - The Lancet Oncology 2019 cited by 796

  5. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 cited by 1,234

  6. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 987

  7. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kim Kihyun, Gracia Martınez, Min Chang‐Ki, Luděk Pour, Xavier Leleu, Albert Oriol, Koh Youngil, Kenshi Suzuki, Tom Martin, Hang Quach, Andrew Lim, Helen Crowther, Hanlon Sia, Cyrille Hulin, Mohamad Mohty, Gábor Mikala, Zsolt Nagy, Marta Reinoso Segura, Laura Rosiñol, Münci Yağcı, Mehmet Turgut, Mamta Garg, Gurdeep Parmar, Brad Augustson, Nelson Castro, Edvan de Queiroz Crusoé, Tomáš Pika, Sosana Delimpasi, Kenichi Ishizawa, Anup George, Т. С. Константинова, Javier de la Rubia, Kim Sung-Hyun, Ângelo Maiolino, Tony Reiman, Richard LeBlanc, Shigeki Ito, Junji Tanaka, А. С. Лучинин, I. V. Kryuchkova, Joaquín Martínez‐López, Jesse Shustik, Lionel Karlin, Anargyros Symeonidis, Miklós Egyed, Mario Petrini, Michèle Cavo, Michihiro Uchiyama, Hilary Blacklock, Mutlu Arat, James E. Griffin, Hannah Hunter, Tonda Buck, Αchilles Anagnostopoulos, Κωνσταντίνος Κωνσταντόπουλος, Tamás Masszi, Sara Bringhen, Barbara Gamberi, Yawara Kawano, Kim Jin Seok, Hakan Özdoğu, Fahir Özkalemkaş - The Lancet 2021 cited by 380

  8. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 363

  9. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

    Authors: , , , , , , , , , , , , , , , , , , , , , - Blood 2011 cited by 1,034

  10. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey Shang-Yi Huang, Jiří Minařík, Michèle Cavo, H. Miles Prince, Sandrine Macé, Kathryn P. Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C. Anderson, Simon J. Harrison, Wojciech Janowski, Ian Kerridge, Andrew Spencer, Michel Delforge, Karel Fostier, Philip Vlummens, Ka Lung Wu, Richard LeBlanc, Michel Pavic, Michaël Sébag, Roman Hájek, Vladimír Maisnar, Luděk Pour, Henrik Gregersen, Lotfi Benbouker, Denis Caillot, Martine Escoffre‐Barbe, Thierry Façon, Laurent Frenzel, Cyrille Hulin, Lionel Karlin, Brigitte Kolb, Brigitte Pegourié, Aurore Perrot, Mourad Tiab, Laure Vincent, Dietger Niederwieser, Αchilles Anagnostopoulos, Sosana Delimpasi, Marie‐Christine Kyrtsonis, Anargyros Symeonidis, Árpád Illés, Gábor Mikala, Zsolt Nagy, Sara Bringen, Paolo Corradini, Fabio Ciceri, Roberto M. Lemoli, Anna Marina Liberati, Chiara Nozzoli, Renato Zambello, Shinsuke Iida, Takashi Ikeda, Satoshi Iyama, Morio Matsumoto, Chihiro Shimazaki, Kazutaka Sunami, Kenshi Suzuki, Michihiro Uchiyama, Youngil Koh, Kihyun Kım, Jae Hoon Lee, Chang‐Ki Min, Hillary Blacklock, Hugh J. B. Goodman, Annette Neylon, David Simpson, Sebastian Grosicki, Artur Jurczyszyn and 30 more - The Lancet 2019 cited by 636

  11. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Raymond L. Comenzo, Monika Engelhardt, Thomas Illmer, Philip Vlummens, Chantal Doyen, Thierry Façon, Lionel Karlin, Aurore Perrot, Klaus Podar, Michael Kauffman, Sharon Shacham, Lingling Li, Shijie Tang, Carla Picklesimer, Jean‐Richard Saint‐Martin, Marsha Crochiere, Hua Chang, Samir Parekh, Yosef Landesman, Jatin J. Shah, Paul G. Richardson, Sundar Jagannath - New England Journal of Medicine 2019 cited by 673

  12. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Mario Boccadoro, Michèle Cavo, Javier de la Rubia Comos, Sosana Delimpasi, Meletios Α. Dimopoulos, Chantal Doyen, Dominik Dytfeld, Monika Engelhardt, Thierry Façon, Roberto Foà, Hartmut Goldschmidt, Sebastian Grosicki, Roman Hájek, Güner Hayri Özsan, Cyrille Hulin, Brian Iversen, Lionel Karlin, Eirini Katodritou, Stefan Knop, Marie‐Christine Kyrtsonis, Juan José Lahuerta, Xavier Leleu, Carmen Martínez Chamorro, María-Victoria Mateos Manteca, Nathalie Meuleman, Monique C. Minnema, Philippe Moreau, Massino Offidani, Albert Oriol Rocafiguera, Mustafa Pehlıvan, Luděk Pour, Henk Roerdink, Laura Rosinol Dacsh, Hans Salwender, Pieter Sonneveld, Anargyros Symeonidis, Charlotte Toftmann Hansen, Tülin Tuğlular, Ali Ünal, Philip Vlummens, Filiz Vural, Ka Lung Wu, Sonja Zweegman - The Lancet Oncology 2021 cited by 327

  13. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tom Willis, Malek Faham, Kenneth C. Anderson, Jean‐Luc Harousseau, Xavier Leleu, Thierry Façon, Philippe Moreau, Michel Attal, Hervé Avet‐Loiseau, Nikhil C. Munshi - Blood 2018 cited by 420

  14. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jelena Bila, Eirini Katodritou, Hanna Oliynyk, Sybiryna Korenkova, Jeevan Kumar, Sundar Jagannath, Philippe Moreau, Moshe Levy, Darrell White, Moshe E. Gatt, Thierry Façon, María‐Victoria Mateos, Michèle Cavo, Donna Reece, Larry D. Anderson, Jean-Richard Saint-Martin, Jacqueline Jeha, Anita Joshi, Yi Chai, Lingling Li, Vishnuvardhan Peddagali, Melina Arazy, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Meletios Α. Dimopoulos, Paul G. Richardson, Sosana Delimpasi - The Lancet 2020 cited by 324

  15. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2015 cited by 762

  16. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Achilleas Anagnostopoulos, Larry D. Anderson, Pekka Anttila, Carla Araujo, Carlos Arce‐Lara, Yıldız Aydın, Supratik Basu, Ramakrishna Battini, Thaddeus Beeker, Lotfi Benboubker, Dina Ben‐Yehuda, Joan Bladé, Igor Wolfgang Blau, Ralph V. Boccia, Lillian Burke, Peter D. Byeff, Nicola Cascavilla, Michèle Cavo, Andrew Chantry, Yen Charles, Arvind Chaudhry, Alessandro Corso, Mark Coyne, Felipe de Arriba, Sosana Delimpasi, Pierre Desjardins, Binod Dhakal, Paolo Di Bartolomeo, Francesco Di Raimondo, Jan Dürig, Monika Engelhardt, Martine Escoffre‐Barbe, Graça Esteves, Max Flogegård, Nashat Gabrail, Barbara Gamberi, Mitchell Garrison, Julie Gay, Heinz Gisslinger, Hartmut Goldschmidt, Cristina Gonçalves, Laurent Gressot, Sebastian Grosicki, Wahid T. Hanna, Patrick Hayden, Maria Manuela Henriques Bernardo, Róbert Hermann, Viran Holden, Kirsti Honkalehto, Marianne Huben, John Huffman, Hannah Hunter, Marek Hus, Madan Jagasia, Sundar Jagganath, Murali Janakiram, Ishmael Jaiyesimi, Matthew Jenner, Cristina João, Peter Johnson, Artur Jurcyszyn, Sevgi Kalayoğlu Beşışık, Suman Kambhampati, Abraham S. Kanate, Ìhsan Karadoǧan, Ali Khojasteh, Dean Kirkel, Mieczysław Komarnicki, Maria‐Theresa Krauth, Phillip Kuriakose and 65 more - The Lancet Oncology 2019 cited by 385

  17. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thierry Façon, P. Andrew Futreal, Kenneth C. Anderson, Peter J. Campbell, Nikhil C. Munshi - Nature Communications 2014 cited by 906

  18. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 243

  19. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Katja Weisel, Rachid Baz, Vânia Hungria, Jesús G. Berdeja, Fernando Leal da Costa, Ângelo Maiolino, Anders Waage, David H. Vesole, Enrique M. Ocio, Hang Quach, Christoph Driessen, Joan Bladé, Xavier Leleu, Eloísa Riva, P. Leif Bergsagel, Jian Hou, Wee Joo Chng, Ulf‐Henrik Mellqvist, Dominik Dytfeld, Jean‐Luc Harousseau, Hartmut Goldschmidt, Jacob P. Laubach, Nikhil C. Munshi, Francesca Gay, Meral Beksaç, Luciano J. Costa, Martin Kaiser, Parameswaran Hari, Mario Boccadoro, Saad Z. Usmani, Sonja Zweegman, Sarah A. Holstein, Orhan Sezer, Simon J. Harrison, Hareth Nahi, Gordon Cook, María‐Victoria Mateos, S. Vincent Rajkumar, Meletios Α. Dimopoulos, Paul G. Richardson - The Lancet Oncology 2021 cited by 268

  20. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mohamed Elemary, Nizar J. Bahlis, Thierry Façon, Lionel Karlin, Vincent Ribrag, Michel Attal, Hartmut Goldschmidt, Monika Engelhardt, Katja Weisel, Andréas Mackensen, Arnon Nagler, Dina Ben Yehuda, Irit Avivi, Noam Benyamini, Hila Magen‐Nativ, Antonio Palumbo, Michèle Cavo, Kensei Tobinai, Shinsuke Iida, Takaai Chou, Kenshi Suzuki, Hiroshi Kosugi, Masafumi Taniwaki, Kazutaka Sunami, Morio Matsumoto, Kiyoshi Ando, Peter Ganly, Hilary Blacklock, David Simpson, Anupkumar George, Fredrik Schjesvold, Bjørn Tore Gjertsen, Juan José Lahuerta, Joan Bladé, Albert Oriol Rocafiguera, María‐Victoria Mateos, Paula Rodríguez‐Otero, Sarah M. Larson, Djordje Atanackovic, Srinivas Devarakonda, Jacob D. Bitran, Jeffrey A. Zonder, Neil Morganstein, Mohammad Hay, Asher Chanan‐Khan, Gene Saylors, Ebenezer A. Kio, Ira Oliff, Dean Kirkel, Mikhail Shtivelband, Carrie Yuen, Andrew J. Yee, Jatin J. Shah, Myo Htut, Shahzad Raza, Saurabh Chhabra, Patrick J. Stiff, Parameswaran Hari, Bruce Bank, Ehsan Malek, Cristina Gasparetto, Ycaoub Faroun, Daniel W. Sherbenou, William Kreisle, Seema Singhal, Jacalyn Rosenblatt, Saad Z. Usmani, Wes Lee, Hana Safah, Jose Lutzky and 21 more - The Lancet Haematology 2019 cited by 253

  21. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood Cancer Journal 2023 cited by 95

  22. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2021 cited by 141

  23. RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tom Moore, Meike Schneider, Wolfgang Jacob, Maja Weisser, Martin Hutchings, Caroline Hasselbalch Riley - Blood 2022 cited by 90

  24. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , - Blood 2017 cited by 527